6WMH
Next generation monomeric IgG4 Fc
Summary for 6WMH
| Entry DOI | 10.2210/pdb6wmh/pdb |
| Descriptor | Immunoglobulin heavy constant gamma 4 (2 entities in total) |
| Functional Keywords | antibody constant region, fragment crystallizable, mutated, immune system |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 2 |
| Total formula weight | 47579.30 |
| Authors | Oganesyan, V.Y.,Shan, L.,van Dyk, N.,Dall'Acqua, W.F. (deposition date: 2020-04-21, release date: 2021-09-15, Last modification date: 2024-11-13) |
| Primary citation | Shan, L.,Dyk, N.V.,Haskins, N.,Cook, K.M.,Rosenthal, K.L.,Mazor, R.,Dragulin-Otto, S.,Jiang, Y.,Wu, H.,Dall'Acqua, W.F.,Borrok, M.J.,Damschroder, M.M.,Oganesyan, V. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. Commun Biol, 4:1048-1048, 2021 Cited by PubMed Abstract: In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life. PubMed: 34497355DOI: 10.1038/s42003-021-02565-5 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report
